NewsSource: EClinCloud

A Top-Tier Tool That Gives Sponsors a Head Start!

3 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration


Editor's Note

Clinical trials are like advancing through stages in a game—choosing the right gear gives you twice the result with half the effort!

Today, we strongly recommend a top-tier tool for clinical trials: "eCOA." Say goodbye to duplicate data entry, migration, and repeated reconciliation across different systems. By capturing high-quality, accurate data, clinical trials can become more efficient and give sponsors a head start!


Vol. 1: Policy Support

For clinical trials, staying up to date on national policies and guidelines is essential to understanding industry developments and operationalizing study implementation plans.


Internationally, on June 16, 2020, the U.S. Food and Drug Administration (FDA) issued "Patient-Focused Drug Development: Collecting Comprehensive and Representative Input" Guidance for Industry, aiming to facilitate the systematic collection of reliable information from patients and caregivers.

To better serve patients, the "patient-centered" value concept has gained prominence, and this concept is put into practice by collecting PROs.


Domestically, the 2021 "Guiding Principles for Using Patient-Reported Outcomes in Drug Clinical Trials (Trial)" states that clinical outcome assessments (COA), and patient-reported outcomes in particular, reflect how patients feel and are an important part of patient-focused drug development. PRO data can be collected using either paper records or electronic media; using electronic means to record PROs is termed electronic patient-reported outcome (ePRO).

Both policy support and technological development are aimed at better serving patients. Clinical outcome assessments (COA) are an indispensable tool for improving drug therapy when collecting and analyzing real-world data (RWD, data obtained by investigators through real-world research) in clinical trials.


Vol. 2: Strong Advantages of eCOA

First, let's clarify what the relationship between eCOA and ePRO is.

COA encompasses four types of outcomes:

PRO (Patient-Reported Outcome)

ClinRO (Clinician-Reported Outcome; outcome reported by a healthcare professional)

ObsRO (Observer-Reported Outcome; outcome reported by an observer)

PerfO (Performance Outcome)


Although PRO is the most widely used of these, it is only one branch encompassed within COA; COA is like the "head of the family," with broader coverage.

Returning to the title, why is eCOA said to have strong advantages?


First, eCOA can be used not only to collect ePRO, eClinRO, eObsRO, and ePerfO, but also to collect custom diaries, such as adverse reactions (SAE), dosing logs, and out-of-hospital examination reports;

Second, compared with eCOA, paper-based completion can suffer from missing entries, incorrect entries, illegible handwriting, or contradictory responses. In another scenario, because patients forget or find it inconvenient, they may fill out all entries for a daily symptom log in one sitting on the day before a follow-up visit, causing data confusion and inaccuracy.


In short, using an eCOA system improves patient compliance through system settings: patients receive daily completion reminders from the system and can avoid certain errors during entry, improving entry accuracy and the completeness of the collected data. Moreover, amid the widespread COVID-19 pandemic, eCOA's remote visit functionality enables better capture of patients' true experiences and higher-quality patient data.

By contrast, "eCOA/ePRO offers clear advantages in data collection accuracy, completeness, efficiency, real-time capture, flexibility, compliance, security, and patient privacy protection."


Vol. 3 In summary

eCOA is not merely about completing questionnaires through a system; it is a way of participating in clinical trials electronically and strictly following CDE requirements (i.e., the eCOA system must maintain a clear audit trail able to confirm the accuracy and authenticity of source data, incorporate strong encryption to ensure patient privacy is protected through permission controls, and prevent data loss throughout the process) to collect data.


Got it?
Using eCOA or ePRO is the prevailing trend
in clinical trials.
Therefore,


EClinCloud provides a one-stop solution


Article illustration
Article illustration

Scroll up and down to browse this bookmark

We provide end-to-end services including scale management, scale training, scale-related medical support, paper scale management, electronic clinical outcome assessment (eCOA), eCOA training, device operations and maintenance management, and quality control, backed by a strong medical team. Among these, the eCOA system and processes are recognized by regulatory authorities such as the FDA, hold over 50% of the global market share, and support you throughout the process with standardized service workflows.

Scan QR code

Contact Us

Article illustration


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.